Neutrophil elastase in obesity-related fatty liver diseases

Information

  • Research Project
  • 10264057
  • ApplicationId
    10264057
  • Core Project Number
    R01DK126949
  • Full Project Number
    5R01DK126949-02
  • Serial Number
    126949
  • FOA Number
    PA-19-056
  • Sub Project Id
  • Project Start Date
    9/15/2020 - 4 years ago
  • Project End Date
    8/31/2023 - a year ago
  • Program Officer Name
    DOO, EDWARD
  • Budget Start Date
    9/1/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    8/30/2021 - 3 years ago
Organizations

Neutrophil elastase in obesity-related fatty liver diseases

Summary Obesity is the primary factor that contributes to the development of nonalcoholic fatty liver diseases (NAFLD), including steatosis and nonalcoholic steatohepatitis (NASH), and fibrosis in the liver. However, the molecular and cellular events that initiate and propagate obesity-related steatosis, inflammatory damage, and fibrotic remodeling in the liver remain unclear. We observed that a fat- and fructose-enriched diet increases pro- inflammatory neutrophil production preceding leukocyte infiltration, lipid deposition, and inflammatory damage in the liver. However, neutrophil elastase (NE) knockout (KO) mice or mice treated with an NE inhibitor are resistant to obesogenic diet-induced inflammation, lipid deposition, and fibrosis in the liver. Based on our preliminary data, we hypothesize that inhibition of NE prevents obesity-induced proinflammatory neutrophil production via altering NAD-dependent deacetylase Sirtuin 1 (Sirt1) signaling pathway in neutrophils. Deletion of NE also activates AMP-kinase (AMPK), increases the expression of peroxisome proliferator-activated receptor alpha (PPAR?), and enhances mitochondrial gene expression and fatty acid oxidation, attenuating obesogenic diet- induced steatosis in the liver. Furthermore, inhibition or deletion of NE mitigates obesogenic diet-induced accumulation of inflammatory macrophages and T-helper 17 cells, inflammatory damage, and collagen deposition in the liver. In this proposal, we will evaluate if Sirt1 in neutrophils, and if PPAR? and AMPK? in the liver are required for the beneficial effects of NE inhibition on diet-induced NASH. To understand how NE inhibition regulates diet-induced liver fibrotic remodeling, we will also explore the molecular basis by which neutrophils interact with other immune and non-immune cells in the liver. Successful completion of this project will shed new light on molecular and cellular mechanisms by which inhibition of NE as a potential therapeutic approach for obesity-related fatty liver diseases.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R01
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
    252467
  • Indirect Cost Amount
    164104
  • Total Cost
    416571
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIDDK:416571\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    HBPP
  • Study Section Name
    Hepatobiliary Pathophysiology Study Section
  • Organization Name
    BOSTON UNIVERSITY MEDICAL CAMPUS
  • Organization Department
    PHARMACOLOGY
  • Organization DUNS
    604483045
  • Organization City
    BOSTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    021182841
  • Organization District
    UNITED STATES